Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies have …

ICI-associated irAEs constitute a new group of neurologic complications of systemic
anticancer therapies. Although potentially severe, these rare neurologic toxicities are often …

Objective To report the clinicopathologic features and outcome of myositis in patients treated
with immune checkpoint inhibitors (ICIs)(irMyositis). Methods We retrospectively analyzed …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

Aim To characterise clinical presentation, laboratory and histopathologic characteristics and
assess the treatment and outcome of neuromuscular side-effects of checkpoint therapy …

Importance Neurological complications are an increasingly recognized consequence of the
use of anti–programmed death 1 (PD-1) antibodies in the treatment of solid-organ tumors …

Immune checkpoint inhibitor (ICI) therapy has revolutionized the management of various
cancers with previously poor prognosis. Despite its great efficacy, the therapy is associated …

Neuromuscular adverse events following cancer treatment with anti-programmed cell death
protein 1 (PD-1) monoclonal antibodies are relatively rare, yet potentially fatal. We …

Abstract Programmed death-1 (PD-1) inhibitors are increasingly used in cancer
immunotherapy. Various immune-related adverse events are reported, including infrequent …

Abstract Purpose of Review In recent years, immune checkpoint inhibitors have been
increasingly used in patients with metastatic cancers with favorable oncological outcomes; …